Emerging DPP-4 inhibitors: focus on linagliptin for type 2 diabetes

References

• The Global Burden [webpage on the Internet] Brussels International Diabetes Federation (IDF) 2011 Available from: http://www.idf.org/diabetesatlas/5e/the-global-burden Accessed 18 December, 2012
   Google Scholar
• Gallwitz B Sitagliptin: profile of a novel DPP-4 inhibitor for the treatment of type 2 diabetes (update) Drugs Today (Barc) 2007 43 801 814 18174966
   PubMed Web of Science ®Google Scholar
• Gallwitz B Sitagliptin with metformin: profile of a combination for the treatment of type 2 diabetes Drugs Today (Barc) 2007 43 681 689 17987221
   PubMed Web of Science ®Google Scholar
• Inzucchi SE Bergenstal RM Buse JB Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Diabetologia 2012 55 1577 1596 22526604
   PubMed Web of Science ®Google Scholar
• German Diabetes Association Matthaei S Bierwirth R Fritsche A Medical antihyperglycaemic treatment of type 2 diabetes mellitus: update of the evidence-based guideline of the German Diabetes Association Exp Clin Endocrinol Diabetes 2009 117 522 557 19876795
   PubMed Web of Science ®Google Scholar
• Drucker DJ Nauck MA The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes Lancet 2007 368 1696 1705 17098089
   PubMed Web of Science ®Google Scholar
• Nauck MA Heimesaat MM Orskov C Holst JJ Ebert R Creutzfeldt W Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus J Clin Invest 1993 91 301 307 8423228
   PubMed Web of Science ®Google Scholar
• Deacon CF Hughes TE Holst JJ Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig Diabetes 1998 47 764 769 9588448
   PubMed Web of Science ®Google Scholar
• Mentlein R Gallwitz B Schmidt WE Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum Eur J Biochem 1993 214 829 835 8100523
   PubMedGoogle Scholar
• Mentlein R Dipeptidyl-peptidase IV (CD26) – role in the inactivation of regulatory peptides Regul Pept 1999 85 9 24 10588446
   PubMed Web of Science ®Google Scholar
• Ahrén B Simonsson E Larsson H Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes Diabetes Care 2002 25 869 875 11978683
   PubMed Web of Science ®Google Scholar
• Thomas L Eckhardt M Langkopf E Tadayyon M Himmelsbach F Mark M (R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methylquinazolin- 2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors J Pharmacol Exp Ther 2008 325 175 182 18223196
   PubMed Web of Science ®Google Scholar
• Eckhardt M Hauel N Himmelsbach F 3,5-Dihydro-imidazo[4,5-d] pyridazin-4-ones: a class of potent DPP-4 inhibitors Bioorg Med Chem Lett 2008 18 3158 3162 18485703
   PubMed Web of Science ®Google Scholar
• Gallwitz B Small molecule dipeptidylpeptidase IV inhibitors under investigation for diabetes mellitus therapy Expert Opin Investig Drugs 2011 20 723 732
   PubMed Web of Science ®Google Scholar
• Eckhardt M Langkopf E Mark M 8-(3-(R)-aminopiperidin- 1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylme thyl)- 3,7-dihydropurine-2,6-dione (BI 1356), a highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 diabetes J Med Chem 2007 50 6450 6453 18052023
   PubMed Web of Science ®Google Scholar
• Deacon CF Holst JJ Linagliptin, a xanthine-based dipeptidyl peptidase- 4 inhibitor with an unusual profile for the treatment of type 2 diabetes Expert Opin Investig Drugs 2010 19 133 140
   PubMed Web of Science ®Google Scholar
• He YL Sadler BM Sabo R The absolute oral bioavailability and population-based pharmacokinetic modelling of a novel dipeptidylpeptidase- IV inhibitor, vildagliptin, in healthy volunteers Clin Pharmacokinet 2007 46 787 802 17713976
   PubMed Web of Science ®Google Scholar
• Herman GA Stein PP Thornberry NA Wagner JA Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: focus on sitagliptin Clin Pharmacol Ther 2007 81 761 767 17392725
   PubMed Web of Science ®Google Scholar
• Huttner S Graefe-Mody EU Withopf B Ring A Dugi KA Safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of BI 1356, an inhibitor of dipeptidyl peptidase 4, in healthy male volunteers J Clin Pharmacol 2008 48 1171 1178 18812608
   PubMed Web of Science ®Google Scholar
• Fuchs H Binder R Greischel A Tissue distribution of the novel DPP-4 inhibitor BI 1356 is dominated by saturable binding to its target in rats Biopharm Drug Dispos 2090 30 229 240 19562682
   PubMed Web of Science ®Google Scholar
• Fuchs H Tillement JP Urien S Greischel A Roth W Concentration-dependent plasma protein binding of the novel dipeptidyl peptidase 4 inhibitor BI 1356 due to saturable binding to its target in plasma of mice, rats and humans J Pharm Pharmacol 2009 61 55 62 19126297
   PubMed Web of Science ®Google Scholar
• Heise T Graefe-Mody EU Hüttner S Ring A Trommeshauser D Dugi KA Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients Diabetes Obes Metab 2009 11 786 794 19476474
   PubMed Web of Science ®Google Scholar
• Horie Y Kanada S Watada H Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor linagliptin: a 4-week multicenter, randomized, double-blind, placebo-controlled phase IIa study in Japanese type 2 diabetes patients Clin Ther 2011 33 973 989 21723606
   PubMed Web of Science ®Google Scholar
• Graefe-Mody EU Padula S Ring A Withopf B Dugi KA Evaluation of the potential for steady-state pharmacokinetic and pharmacodynamic interactions between the DPP-4 inhibitor linagliptin and metformin in healthy subjects Curr Med Res Opin 2009 25 1963 1972 19552619
   PubMed Web of Science ®Google Scholar
• Graefe-Mody EU Jungnik A Ring A Woerle HJ Dugi KA Evaluation of the pharmacokinetic interaction between the dipeptidyl peptidase-4 inhibitor linagliptin and pioglitazone in healthy volunteers Int J Clin Pharmacol Ther 2010 48 652 661 20875371
   PubMed Web of Science ®Google Scholar
• Friedrich C Ring A Brand T Sennewald R Graefe-Mody EU Woerle HJ Evaluation of the pharmacokinetic interaction after multiple oral doses of linagliptin and digoxin in healthy volunteers Eur J Drug Metab Pharmacokinet 2011 36 17 24 21340661
   PubMed Web of Science ®Google Scholar
• Graefe-Mody U Rose P Ring A Zander K Iovino M Woerle HJ Assessment of the pharmacokinetic interaction between the novel DPP-4 inhibitor linagliptin and a sulfonylurea, glyburide, in healthy subjects Drug Metab Pharmacokinet 2011 26 123 129 21084763
   PubMed Web of Science ®Google Scholar
• Friedrich C Metzmann K Rose P Matteus M Pinnetti S Woerle HJ Pharmacokinetics and pharmacodynamics of BI10773, a sodium glucose cotransporter-2 (SGLT-2) inhibitor, and linagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, following co-administration in healthy volunteers Diabetes 2011 60 Suppl 1 2327-PO
   Google Scholar
• Del Prato S Barnett AH Huisman H Neubacher D Woerle HJ Dugi KA Effect of linagliptin monotherapy on glycaemic control and markers of beta-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial Diabetes Obes Metab 2011 13 258 267 21205122
   PubMed Web of Science ®Google Scholar
• Kawamori R Inagaki N Araki E Linagliptin monotherapy provides superior glycaemic control versus placebo or voglibose with comparable safety in Japanese patients with type 2 diabetes: a randomized, placebo and active comparator-controlled, double-blind study Diabetes Obes Metab 2012 14 348 357 22145698
   PubMed Web of Science ®Google Scholar
• Taskinen MR Rosenstock J Tamminen I Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study Diabetes Obes Metab 2011 13 65 74 21114605
   PubMed Web of Science ®Google Scholar
• Owens DR Swallow R Dugi KA Woerle HJ Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study Diabet Med 2011 28 1352 1361 21781152
   PubMed Web of Science ®Google Scholar
• Gallwitz B Rosenstock J Rauch T 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial Lancet 2012 380 475 483 22748821
   PubMed Web of Science ®Google Scholar
• Haak T Meinicke T Jones R Weber S von Eynatten M Woerle HJ Initial combination of linagliptin and metformin improves glycaemic control in type 2 diabetes: a randomized, double-blind, placebo-controlled study Diabetes Obes Metab 2012 14 565 574 22356132
   PubMed Web of Science ®Google Scholar
• Gomis R Espadero RM Jones R Woerle HJ Dugi KA Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study Diabetes Obes Metab 2011 13 653 661 21410628
   PubMed Web of Science ®Google Scholar
• Schernthaner G Barnett AH Emser A Safety and tolerability of linagliptin: a pooled analysis of data from randomized controlled trials in 3572 patients with type 2 diabetes mellitus Diabetes Obes Metab 2012 14 470 478 22268497
   PubMed Web of Science ®Google Scholar
• Yazbeck R Howarth GS Abbott CA Dipeptidyl peptidase inhibitors, an emerging drug class for inflammatory disease? Trends Pharmacol Sci 2009 30 600 607 19837468
   PubMed Web of Science ®Google Scholar
• Schürmann C Linke A Engelmann-Pilger K The dipeptidyl peptidase-4 inhibitor linagliptin attenuates inflammation and accelerates epithelialization in wounds of diabetic ob/ob mice J Pharmacol Exp Ther 2012 342 71 80 22493041
   PubMed Web of Science ®Google Scholar
• Klein T Niessen HG Ittrich C Evaluation of body fat composition after linagliptin treatment in a rat model of diet-induced obesity: a magnetic resonance spectroscopy study in comparison with sibutramine Diabetes Obes Metab 2012 14 1050 1053 22651241
   PubMed Web of Science ®Google Scholar
• Hocher B Sharkovska Y Mark M Klein T Pfab T The novel DPP-4 inhibitors linagliptin and BI 14361 reduce infarct size after myocardial ischemia/reperfusion in rats Int J Cardiol Epub January 2, 2012
   Web of Science ®Google Scholar
• Johansen OE Neubacher D von Eynatten M Patel S Woerle HJ Cardiovascular safety of linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme Cardiovasc Diabetol 2012 11 3 22234149
   PubMed Web of Science ®Google Scholar
• Gallwitz B Linagliptin-a novel dipeptidyl peptidase inhibitor for type 2 diabetes therapy Clin Med Insights Endocrinol Diabetes 2012 5 1 11 22879795
   PubMedGoogle Scholar
• Scheen AJ Paquot N Gliptin versus a sulphonylurea as add-on to metformin Lancet 2012 380 450 452 22748818
   PubMed Web of Science ®Google Scholar
• Scheen AJ Van Gaal LF Linagliptin (Trajenta): a selective DPP-4 inhibitor with limited renal elimination Rev Med Liege 2012 67 91 97 French 22482239
   PubMedGoogle Scholar